---
title: "Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297209220.md"
description: "On Thursday, the drug Tezspire, developed by Amgen and AstraZeneca, demonstrated effectiveness in treating an esophageal disease prevalent among approximately 470,000 patients in the United States. The success of Tezspire has raised speculations about its potential to compete with Dupixent, as reported by Investor's Business Daily."
datetime: "2026-08-27T15:16:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297209220.md)
  - [en](https://longbridge.com/en/news/297209220.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297209220.md)
generator: "portal-rs"
---

# Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?

On Thursday, the drug Tezspire, developed by Amgen and AstraZeneca, demonstrated effectiveness in treating an esophageal disease prevalent among approximately 470,000 patients in the United States. The success of Tezspire has raised speculations about its potential to compete with Dupixent, as reported by Investor's Business Daily.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China](https://longbridge.com/en/news/297606938.md)
- [UK regulator suspends Amgen's Tavneos for new patients over unreliable data](https://longbridge.com/en/news/297642592.md)
- [AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories](https://longbridge.com/en/news/297649754.md)
- [China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial](https://longbridge.com/en/news/297148879.md)
- [TEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS | AMGN Stock News](https://longbridge.com/en/news/297131330.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**